Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by A. Bot
Product Characteristics Associated With in Vivo Expansion of Anti-Cd19 Car T Cells in Patients Treated With Axicabtagene Ciloleucel (Axi-Cel)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Related publications
Safety and Efficacy of Axicabtagene Ciloleucel (Axi-Cel) in Older Patients: Results From the Us Lymphoma Car-T Consortium
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Preliminary Results of Earlier Steroid Use With Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Large B Cell Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Prediction of CAR T-Related Toxicities in R/R DLBCL Patients Treated With Axicabtagene Ciloleucel Using Point of Care Cytokine Measurements
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Axicabtagene Ciloleucel for CD19+ Plasmablastic Lymphoma
American Journal of Hematology
Hematology
Axicabtagene Ciloleucel (Axi-Cel; KTE-C19) in Patients With Refractory Aggressive Non-Hodgkin Lymphoma (NHL): Long-Term Follow-Up of the Pivotal Zuma-1 Trial
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Outcomes of Patients ≥ 65 Years of Age in Zuma-1, a Pivotal Phase 1/2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Refractory Large B Cell Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Potent Anti-Leukemia Activities of Humanized CD19-targeted CAR-T Cells in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
American Journal of Hematology
Hematology
Durable Molecular Remission in a Lymphoid BP-CML Patient Harboring T315I Mutation Treated With Anti-Cd19 CAR-T Therapy
OncoTargets and Therapy
Oncology
Pharmacology
Expansion Deficiency of CAR-T Cells in Patients With Lymphoma and Resolution by T Cell Purification
British Journal of Haematology
Hematology
